Last Updated on August 26, 2021 by The Health Master
Following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, Lupin Healthcare has launched Luforbec (beclometasone / formoterol) 100/6 dose pressurised metered dose inhaler (pMDI).
It is available now to patients in the UK, with the potential to offer significant cost savings for the NHS, the company said in a statement.
Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50 per cent predicted normal).
Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US, added the statement.
Merck launches Pergoveris Pen for Infertility treatment in India
Alkem launches Ibuprofen, Famotidine tablets
Zydus Cadila gets final nod from USFDA for Fulvestrant injection
USFDA inspection ends with ‘Zero’ observations: Alkem
Granules Pharma clears USFDA audit
Zydus Cadila gets USFDA nod for Ibrutinib tablets
Latest Notifications regarding Pharmaceuticals
Proposed Pharma cluster: Rs 400 crore investment
Pfizer becomes first Covid vaccine globally to get full USFDA approval
3 Labs booked for Prenatal testing without permission
J&J submits application to CDSCO for study of Covid-19 vaccine on…
High court denied bail in Drug seizure case
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
